What are the benefits and risks of SGLT-2 inhibitors and GLP-1 receptor agonists in T2DM patients with a risk of cardiovascular and renal diseases? A systematic review and meta-analysis considers the variation in benefits and risks with individual risk profile patients. Here’s a Journal Watch that summarizes this study titled “Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: Systematic review and network meta-analysis of randomised controlled trials” , published in BMJ Clinical Research , 2021 .
Swipe through to know the findings! Based on the evidence, would you consider using SGLT-2 inhibitors and GLP-1 receptor agonists for treating patients with T2DM and associated cardiac and renal disease risks?
